NASDAQ
7.38USD
-0.09 (-1.20%)
We have scored 10 news catalysts on Evolus, Inc. (EOLS) over the past 12 months. The biggest single-day move next to one of them came Aug 6, 2026, when EOLS closed +19.9%: “Evolus, Inc. (EOLS) Reports Break-Even Earnings for Q2”. Coverage across the window leans positive (average ticker sentiment +0.18). Most of the impact sits in short squeeze potential and sector healthcare.
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
486M
P/E
—
EPS
—
Beta
1.34
52W range
3.86-9.31
Day range
7.16–7.57
Open
7.47
Prev close
7.47
Volume
663.9K
Avg volume
868.5K
Dividend
0.00
IPO
2018-02-08
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about Evolus, Inc. — not a sector bucket. Click an edge to see the articles that established the link.
Latest scored catalyst for EOLS: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Evolus, Inc. is a performance beauty enterprise that furnishes the United States market with medical aesthetic solutions for healthcare professionals and their patients. A key product in its portfolio is Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation. This product is specifically designed for adults seeking the temporary smoothing of moderate to severe glabellar (frown) lines. Founded in 2012, Evolus, Inc. maintains its corporate headquarters in Newport Beach, California.
